NASDAQ:OMCL Omnicell (OMCL) Stock Price, News & Analysis $32.59 -0.69 (-2.07%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$32.59 0.00 (0.00%) As of 08/29/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Omnicell Stock (NASDAQ:OMCL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Omnicell alerts:Sign Up Key Stats Today's Range$32.51▼$33.4550-Day Range$26.88▼$33.6252-Week Range$22.66▼$55.74Volume595,171 shsAverage Volume577,128 shsMarket Capitalization$1.50 billionP/E Ratio65.18Dividend YieldN/APrice Target$46.71Consensus RatingModerate Buy Company Overview Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas. Read More Omnicell Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreOMCL MarketRank™: Omnicell scored higher than 71% of companies evaluated by MarketBeat, and ranked 431st out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingOmnicell has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageOmnicell has only been the subject of 2 research reports in the past 90 days.Read more about Omnicell's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth13.76% Earnings GrowthEarnings for Omnicell are expected to grow by 13.76% in the coming year, from $1.09 to $1.24 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Omnicell is 65.18, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 268.93.Price to Earnings Ratio vs. SectorThe P/E ratio of Omnicell is 65.18, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 83.11.Price to Earnings Growth RatioOmnicell has a PEG Ratio of 7.27. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioOmnicell has a P/B Ratio of 1.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Omnicell's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.56% of the float of Omnicell has been sold short.Short Interest Ratio / Days to CoverOmnicell has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Omnicell has recently increased by 6.81%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOmnicell does not currently pay a dividend.Dividend GrowthOmnicell does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.56% of the float of Omnicell has been sold short.Short Interest Ratio / Days to CoverOmnicell has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Omnicell has recently increased by 6.81%, indicating that investor sentiment is decreasing significantly. News and Social Media2.9 / 5News Sentiment1.20 News SentimentOmnicell has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.04 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Omnicell this week, compared to 7 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Omnicell insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.52% of the stock of Omnicell is held by insiders.Percentage Held by Institutions97.70% of the stock of Omnicell is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Omnicell's insider trading history. Receive OMCL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Omnicell and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OMCL Stock News HeadlinesQ2 Earnings Highlights: Omnicell (NASDAQ:OMCL) Vs The Rest Of The Healthcare Technology for Providers StocksAugust 28 at 8:24 PM | finance.yahoo.comOmnicell names Baird Radford CFOAugust 26, 2025 | msn.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough. | Brownstone Research (Ad)Omnicell appoints Baird Radford as Executive VP and CFOAugust 25, 2025 | msn.comOmnicell Appoints New CFO Baird RadfordAugust 25, 2025 | tipranks.comOmnicell Appoints Baird Radford as Executive Vice President and Chief Financial OfficerAugust 25, 2025 | mms.businesswire.comOmnicell Appoints Baird Radford as Executive Vice President and Chief Financial OfficerAugust 25, 2025 | businesswire.comOMCL Q2 Deep Dive: Product Innovation and Recurring Revenue Drive Upbeat GuidanceAugust 14, 2025 | finance.yahoo.comSee More Headlines OMCL Stock Analysis - Frequently Asked Questions How have OMCL shares performed this year? Omnicell's stock was trading at $44.52 at the start of the year. Since then, OMCL stock has decreased by 26.8% and is now trading at $32.59. How were Omnicell's earnings last quarter? Omnicell, Inc. (NASDAQ:OMCL) released its quarterly earnings results on Thursday, July, 31st. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.30 by $0.15. The firm's revenue for the quarter was up 5.0% compared to the same quarter last year. Read the conference call transcript. Does Omnicell have any subsidiaries? The following companies are subsidiaries of Omnicell: MarkeTouch Media LLC, ReCept Pharmacy, FDS Amplicare, 340B Link Business, InPharmics, Ateb Inc., Aesynt, and others. Who are Omnicell's major shareholders? Top institutional investors of Omnicell include Lazard Asset Management LLC (3.72%), Sumitomo Mitsui Trust Group Inc. (3.04%), Geode Capital Management LLC (2.55%) and Qube Research & Technologies Ltd (1.42%). Insiders that own company stock include Randall A Lipps, Mark W Parrish, Scott Peter Seidelmann, Joanne B Bauer and Christine Marie Mellon. View institutional ownership trends. How do I buy shares of Omnicell? Shares of OMCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Omnicell own? Based on aggregate information from My MarketBeat watchlists, some other companies that Omnicell investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and Palo Alto Networks (PANW). Company Calendar Last Earnings7/31/2025Today8/29/2025Next Earnings (Estimated)10/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MEDICAL INFO SYS Sub-IndustryHealth Care Technology Current SymbolNASDAQ:OMCL CIK926326 Webwww.omnicell.com Phone(877) 415-9990Fax847-596-3402Employees3,670Year Founded1992Price Target and Rating Average Price Target for Omnicell$46.71 High Price Target$64.00 Low Price Target$34.00 Potential Upside/Downside+43.3%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$0.50 Trailing P/E Ratio65.18 Forward P/E Ratio29.90 P/E Growth7.26Net Income$12.53 million Net Margins2.01% Pretax Margin3.14% Return on Equity4.27% Return on Assets2.44% Debt Debt-to-Equity Ratio0.13 Current Ratio1.42 Quick Ratio1.24 Sales & Book Value Annual Sales$1.11 billion Price / Sales1.35 Cash Flow$3.00 per share Price / Cash Flow10.86 Book Value$27.51 per share Price / Book1.18Miscellaneous Outstanding Shares45,930,000Free Float44,776,000Market Cap$1.50 billion OptionableOptionable Beta0.78 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:OMCL) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omnicell, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Omnicell With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.